Literature DB >> 22687408

The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells.

Chizuka Higashi1, Chiaki Saji, Koji Yamada, Hiroki Kagawa, Rie Ohga, Takahiro Taira, Masahiro Fujimuro.   

Abstract

Primary effusion lymphoma (PEL) is an aggressive neoplasm caused by Kaposi's sarcoma-associated herpesvirus (KSHV) in immunosuppressed patients and human immunodeficiency virus (HIV)-infected homosexual males. We evaluated the cytotoxic effects of heat shock protein 90 (HSP90) inhibitors on PEL cells. The HSP90 inhibitors geldanamycin (GA), 17(allylamino)-17-demethoxygeldanamycin (17-AAG), and radicicol dramatically inhibited cell proliferation and induced apoptosis of PEL cells through caspase activation. Furthermore, GA induced the stabilization of inhibitor of κB (IκB)α and reduced the phosphorylation of IκBα in PEL cells. HSP90 inhibitors suppressed the transcriptional activity of nuclear factor-kappa B (NF-κB) in PEL cells. It is known that the constitutive activation of NF-κB signaling is essential for the survival of PEL cells and HSP90 contributes to promote activation of NF-κB signaling. The suppression of NF-κB signaling by HSP90 inhibitors may contribute to the induction of apoptosis in PEL cells. In addition, HSP90 activity is required for KSHV replication in KSHV latently infected PEL cells. GA, 17-AAG and radicicol reduced the production of progeny virus from PEL cells at low concentrations, which do not affect PEL cell growth. Our results suggest that HSP90 activity is required for both the survival of PEL cells and viral replication in PEL cells, and that pharmacologic inhibition of HSP90 may be an effective treatment for PEL and KSHV-related diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22687408     DOI: 10.1248/bpb.35.725

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  8 in total

1.  A purine scaffold HSP90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP K13-induced NF-κB.

Authors:  Ramakrishnan Gopalakrishnan; Hittu Matta; Preet M Chaudhary
Journal:  Clin Cancer Res       Date:  2013-07-23       Impact factor: 12.531

2.  Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.

Authors:  Utthara Nayar; Pin Lu; Rebecca L Goldstein; Jelena Vider; Gianna Ballon; Anna Rodina; Tony Taldone; Hediye Erdjument-Bromage; Max Chomet; Ronald Blasberg; Ari Melnick; Leandro Cerchietti; Gabriela Chiosis; Y Lynn Wang; Ethel Cesarman
Journal:  Blood       Date:  2013-08-13       Impact factor: 22.113

3.  Natural Killer cell-dependent and non-dependent anti-viral activity of 2-Cys Peroxiredoxin against HIV.

Authors:  Mohammed Asmal; Norman L Letvin; Ralf Geiben-Lynn
Journal:  Int Trends Immun       Date:  2013-10

4.  Primary effusion lymphoma in an elderly patient effectively treated by lenalidomide: case report and review of literature.

Authors:  A Antar; H El Hajj; M Jabbour; I Khalifeh; F El-Merhi; R Mahfouz; A Bazarbachi
Journal:  Blood Cancer J       Date:  2014-03-07       Impact factor: 11.037

Review 5.  Targeting of prosurvival pathways as therapeutic approaches against primary effusion lymphomas: past, present, and Future.

Authors:  Marisa Granato; Roberta Santarelli; Roberta Gonnella; Antonella Farina; Pankaj Trivedi; Alberto Faggioni; Mara Cirone
Journal:  Biomed Res Int       Date:  2015-01-28       Impact factor: 3.411

6.  A pyridinium‑type fullerene derivative suppresses primary effusion lymphoma cell viability via the downregulation of the Wnt signaling pathway through the destabilization of β‑catenin.

Authors:  Ayano Kadota; Misato Moriguchi; Tadashi Watanabe; Yuichi Sekine; Shigeo Nakamura; Takumi Yasuno; Tomoyuki Ohe; Tadahiko Mashino; Masahiro Fujimuro
Journal:  Oncol Rep       Date:  2022-01-11       Impact factor: 3.906

7.  Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins.

Authors:  Wuguo Chen; Sang-Hoon Sin; Kwun Wah Wen; Blossom Damania; Dirk P Dittmer
Journal:  PLoS Pathog       Date:  2012-11-29       Impact factor: 6.823

Review 8.  Recent Advances in Developing Treatments of Kaposi's Sarcoma Herpesvirus-Related Diseases.

Authors:  Eleonora Naimo; Jasmin Zischke; Thomas F Schulz
Journal:  Viruses       Date:  2021-09-09       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.